🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

953 results for “injection” Clear

  1. Sodium Chloride Injection/ DEMO 0,9% w/v, EMAPALUMAB

    The George Institute

    SEPSIS

    phase 2 small molecule active

    1 trial
  2. Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen

    NovoThirteen

    SGA - small for gestational age children

    phase 2 small molecule active

    1 trial
  3. Solution for injection in pre-filled syringe

    Alphapharm Pty Ltd

    Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)

    phase 2 small molecule active

    1 trial
  4. SonoVue 8 microlitres/mL powder and solvent for dispersion for injection, CARBOPLATIN

    Pari Pharma GmbH

    recurrent primary supratentorial malignant brain tumors in children

    phase 2 small molecule active

    1 trial
  5. Stellate Ganglion Block injection with ropivicane

    United Therapeutics Europe Ltd

    Post Traumatic Stress Disorder (PTSD)

    phase 2 other completed

    1 trial
  6. Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept

    Regeneron UK Limited

    Thyroid Eye Disease

    phase 2 small molecule completed

    1 trial
  7. Subcutaneous injection of TAK-850

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial
  8. Sugammadex Injection 2mg/kg

    BRIGHT MINDS BIOSCIENCES INC.

    Anesthesia, General

    phase 2 small molecule completed

    1 trial
  9. TAK-850 0.5 mL injection

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial
  10. TAMBICICLIB 100 mg/10 mL, Solution for Injection, AZACITIDINE , TAMBICICLIB 100 mg/20 mL, Solution for Injection, VENETOCLAX

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 2 small molecule active

    1 trial
  11. TEPADINA 15 mg powder for concentrate for solution for infusion, Trecondi 5 g powder for solution for infusion, Mozobil 20 mg/ml solution for injection, Trecondi 5 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded.

    Fondazione Telethon ETS

    Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene

    phase 2 small molecule active

    1 trial
  12. TIN816, Placebo to TIN816 70mg powder for solution for injection or infusion

    Novartis Pharmaceuticals

    Acute kidney injury

    phase 2 small molecule active

    1 trial
  13. TNX-1300 (Injection)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use

    phase 2 small molecule terminated

    1 trial
  14. TQC2731 injection

    Shanghai University of Traditional Chinese Medicine

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial
  15. TQH2722 injection

    Shanghai University of Traditional Chinese Medicine

    Seasonal Allergic Rhinitis

    phase 2 small molecule active

    1 trial
  16. Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    The George Institute

    Adult participants with metastatic (advanced) solid tumors.

    phase 2 small molecule active

    1 trial
  17. The placebo will consist solely of the excipients of eblasakimab, i.e., the same formulation without the active ingredient and will be identical in appearance to eblasakimab. Pharmaceutical form: Solution for SC injection

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial
  18. Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections

    The First People's Hospital of Lianyungang

    Hematological Malignancy

    phase 2 small molecule active

    1 trial
  19. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial
  20. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial
  21. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Obesity &Amp; Overweight

    phase 2 small molecule completed

    1 trial
  22. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule completed

    1 trial
  23. Ubamatamab, TOCILIZUMAB, Ubamatamab, Kevzara 175 mg/ml solution for injection, CEMIPLIMAB, LIBTAYO 350 mg concentrate for solution for infusion., Sarilumab

    Lacuna Pharma Pty Ltd

    Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer

    phase 2 small molecule active

    1 trial
  24. VAY736, Placebo Solution for injection or infusion 0 mg/1 mL

    Novartis Pharmaceuticals

    Moderate to severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources